Tardif JC - Search Results

1

Vascular protectants for the treatment of atherosclerosis.

Tardif JC, Grégoire J, Lavoie MA, L'Allier PL. Tardif JC, et al. Expert Rev Cardiovasc Ther. 2003 Sep;1(3):385-92. doi: 10.1586/14779072.1.3.385. Expert Rev Cardiovasc Ther. 2003. PMID: 15030266 Review.

2

Effects of plaque composition on vascular remodelling after angioplasty in the MultiVitamins and Probucol (MVP) trial.

Lee HS, Tardif JC, Harel F, Côté G, Joyal M, Gosselin G, L'Allier PL, Doucet S, de Guise P, Lespérance J, Grégoire JC, Couturier A. Lee HS, et al. Among authors: tardif jc. Can J Cardiol. 2002 Mar;18(3):271-5. Can J Cardiol. 2002. PMID: 11907616 Clinical Trial.

3

Design features of the Avasimibe and Progression of coronary Lesions assessed by intravascular UltraSound (A-PLUS) clinical trial.

Tardif JC, Grégoire J, Lespérance J, Lambert J, L'Allier PL, Rodés J, Anderson T, Blue JW, Imus J, Heinonen T. Tardif JC, et al. Am Heart J. 2002 Oct;144(4):589-96. doi: 10.1067/mhj.2002.125329. Am Heart J. 2002. PMID: 12360153 Clinical Trial.

4

Effects of AGI-1067 and probucol after percutaneous coronary interventions.

Tardif JC, Grégoire J, Schwartz L, Title L, Laramée L, Reeves F, Lespérance J, Bourassa MG, L'Allier PL, Glass M, Lambert J, Guertin MC; Canadian Antioxidant Restenosis Trial (CART-1) Investigators. Tardif JC, et al. Circulation. 2003 Feb 4;107(4):552-8. doi: 10.1161/01.cir.0000047525.58618.3c. Circulation. 2003. PMID: 12566365 Clinical Trial.

5

Clinical results with AGI-1067: a novel antioxidant vascular protectant.

Tardif JC. Tardif JC. Am J Cardiol. 2003 Feb 6;91(3A):41A-49A. doi: 10.1016/s0002-9149(02)03149-1. Am J Cardiol. 2003. PMID: 12645643 Review.

6

Detection of myocardial perfusion abnormalities after a recent acute coronary syndrome by quantitative Levovist myocardial contrast echocardiography: comparison with 99m Tc-Myoview SPECT imaging.

Fernandes LP, Tardif JC, Arsenault A, Grégoire J, Basmadjian A, Couturier A, Vannan M. Fernandes LP, et al. Among authors: tardif jc. Can J Cardiol. 2003 Mar 15;19(3):251-6. Can J Cardiol. 2003. PMID: 12677280

7

Pharmacologic prevention of both restenosis and atherosclerosis progression: AGI-1067, probucol, statins, folic acid and other therapies.

Tardif JC, Grégoire J, Lavoie MA, L'Allier PL. Tardif JC, et al. Curr Opin Lipidol. 2003 Dec;14(6):615-20. doi: 10.1097/00041433-200312000-00010. Curr Opin Lipidol. 2003. PMID: 14624139 Review.

8

Prevention of restenosis with antioxidants: mechanisms and implications.

Tardif JC, Grégoire J, L'Allier PL. Tardif JC, et al. Am J Cardiovasc Drugs. 2002;2(5):323-34. doi: 10.2165/00129784-200202050-00005. Am J Cardiovasc Drugs. 2002. PMID: 14727962 Review.

9

Intravascular ultrasound assessment of atherosclerosis.

Guédès A, Tardif JC. Guédès A, et al. Among authors: tardif jc. Curr Atheroscler Rep. 2004 May;6(3):219-24. doi: 10.1007/s11883-004-0035-4. Curr Atheroscler Rep. 2004. PMID: 15068747 Review.

10

Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation.

L'Allier PL, Ducharme A, Keller PF, Yu H, Guertin MC, Tardif JC. L'Allier PL, et al. Among authors: tardif jc. J Am Coll Cardiol. 2004 Jul 7;44(1):159-64. doi: 10.1016/j.jacc.2004.03.056. J Am Coll Cardiol. 2004. PMID: 15234426 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

794 results

Search Page